Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This abstract does not contain research results or findings.

This study compared intralesional betamethasone and triamcinolone acetonide for treating alopecia areata and found that both were effective, with betamethasone 1.75mg/ml showing similar results to triamcinolone at 12 weeks without adverse effects.

This case series found that combining ablative fractional resurfacing and acoustic pressure ultrasound with triamcinolone treatment led to complete recovery in patients with areata alopecia.

In this study, intradermal injection of botulinum toxin type A significantly increased hair count and improved physician-assessed hair condition in men with male pattern baldness after 24 weeks, with no serious adverse events reported beyond temporary local pain and redness.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This review discusses the evaluation, diagnosis, and management of beard alopecia areata and reports no new clinical results, though it highlights recent treatment advances with janus kinase inhibitors.

This review discusses the potential role of brown adipose tissue in managing polycystic ovary syndrome and reports no new clinical results; it highlights a need for further research on this therapeutic avenue.

In a systematic review and meta-analysis, the researchers found that intralesional triamcinolone acetonide was more effective than cryotherapy for achieving significant hair regrowth in patients with patchy alopecia areata, although both treatments had distinct safety profiles.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

In this study, novel mutations in the BTD gene were identified in a patient with profound biotinidase deficiency, highlighting the importance of biotinidase activity measurement and mutation analysis for early diagnosis.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This study found that prolonged acute tissue expansion notably increased the amount of scalp tissue removed during scalp reduction surgery in three patients.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This study of baricitinib in adults with severe alopecia areata found that after initial success, 10.9% of participants lost treatment response by Week 152. Factors like longer disease duration and severe baseline symptoms were more common in those losing response.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This study found that a short-term treatment with all-trans retinoic acid may effectively stabilize platelet counts in idiopathic thrombocytopenic purpura patients experiencing fluctuations during thrombopoietin receptor agonist therapy.

This study observed that treating acne scars with fractional ablative laser concurrently with isotretinoin improved outcomes more effectively compared to applying the laser 6 months after isotretinoin treatment ended, as measured by the Quantitative Global Acne Scarring Grading System.

In this pilot study, cryotherapy using a device that precisely controls cooling duration improved hair regrowth for patchy alopecia areata when applied for 20 seconds with two freeze-thaw cycles, similar to standard triamcinolone acetonide injections, but not when applied for 10 seconds.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

In this study, 65% TCA showed better improvement for acne scars compared to 50% GA, but GA may be a safer alternative with fewer adverse effects.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study suggests that peri-incisional triamcinolone acetonide may subtly benefit wound edge apposition in low-tension scalp regions during hair restoration surgery, but shows no statistically significant overall effect.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.